Draupnir Bio

Private

CopenhagenHealthcare & Life Scienceshttps://draupnir.bio/

Last Round

Seed

Jul 17, 2024

Total Funding Raised

$48.91M

Company Overview

Draupnir Bio is a biotechnology company that develops oral, small molecule degraders of extracellular disease-causing proteins by harnessing the natural machinery of the lysosome.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

targeted protein degradationextracellular protein degradationSORTACsmall molecule degradersTPDoral protein degradersundruggable targetslysosome targeting chimeraLYTACdrug discovery platformmembrane protein degradationsortilinpreclinical pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Draupnir Bio Comps

Public and private peers based on sector, stage, and business model.

Draupnir Bio comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Draupnir Bio Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Seed	Jul 17, 2024
Series A	Oct 1, 2019
Grant	Nov 30, 2017
Seed	Apr 1, 2017

View all Funding Rounds

Key People

Founding team and executive leadership

Andrew Hotchkiss

Chief Executive Officer

Executive Team

Draupnir Bio Investors

Notable investors and investment history

Draupnir Bio investors
Investor	Rounds
Novo Nordisk Foundation	Grant
MP Healthcare Venture Management	Seed
Gilde Healthcare	Seed, Series A
Novo Holdings	Seed
The Export and Investment Fund of Denmark	Seed
Inkef Capital	Seed, Series A
High-Tech Gründerfonds	Seed, Series A

View all Investors

Draupnir Bio Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Draupnir Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Draupnir Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCopenhagen

Employee Range16

Year Founded2017

Last FundingJul 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.